Enzymatica publ AB - Asset Resilience Ratio
Enzymatica publ AB (ENZY) has an Asset Resilience Ratio of 22.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ENZY current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Enzymatica publ AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Enzymatica publ AB assets under control.
Liquid Assets Composition Over Time
This chart breaks down Enzymatica publ AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ENZY strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr33.08 Million | 22.17% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr33.08 Million | 22.17% |
Asset Resilience Insights
- Good Liquidity Position: Enzymatica publ AB maintains a healthy 22.17% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Enzymatica publ AB Industry Peers by Asset Resilience Ratio
Compare Enzymatica publ AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Enzymatica publ AB (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Enzymatica publ AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 38.53% | Skr75.21 Million ≈ $8.09 Million |
Skr195.22 Million ≈ $21.01 Million |
+31.88pp |
| 2023-12-31 | 6.64% | Skr8.37 Million ≈ $900.32K |
Skr125.91 Million ≈ $13.55 Million |
-22.42pp |
| 2022-12-31 | 29.06% | Skr50.69 Million ≈ $5.45 Million |
Skr174.41 Million ≈ $18.77 Million |
+8.93pp |
| 2021-12-31 | 20.13% | Skr31.62 Million ≈ $3.40 Million |
Skr157.04 Million ≈ $16.90 Million |
+5.31pp |
| 2020-12-31 | 14.82% | Skr24.02 Million ≈ $2.58 Million |
Skr162.03 Million ≈ $17.44 Million |
-- |
About Enzymatica publ AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.